Publications

APCARI > Blog > Publications > Detection of circulating tumor cells using targeted surface-enhanced Raman scattering nanoparticles and magnetic enrichment

Publications

Detection of circulating tumor cells using targeted surface-enhanced Raman scattering nanoparticles and magnetic enrichment

By:
Contributors: Robert Paproski, PhD, Ronald Moore Research Group
J Biomed Opt. 2014 May;19(5):056014. doi: 10.1117/1.JBO.19.5.056014.
Shi W1, Paproski RJ1, Moore R2, Zemp R1.

Abstract

While more than 90% of cancer deaths are due to metastases, our ability to detect circulating tumor cells (CTCs) is limited by low numbers of these cells in the blood and factors confounding specificity of detection. We propose a magnetic enrichment and detection technique for detecting CTCs with high specificity. We targeted both magnetic and surface-enhanced Raman scattering (SERS) nanoparticles to cancer cells. Only cells that are dual-labeled with both kinds of nanoparticles demonstrate an increasing SERS signal over time due to magnetic trapping.

PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Publications

Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients Posted on Mar 13 22 at 11:10am
Analysis of the role of PI3K-AKT and DNA damage repair (DDR) genomic biomarkers as predictors of clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC) Posted on Feb 16 22 at 11:47am
A prostate cancer risk calculator (PCRC-MRI): Use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men Posted on Feb 3 22 at 2:00pm

Thank you for attending the APCaRI Fall Symposium 2022!

The APCaRI Fall Symposium 2022, held November 18-19, was a huge success! We thank our keynote speakers Dr. Chris Wallis, Dr. Paul Boutros, and Mr. Vijay Pandurangan for joining us in beautiful Banff, Alberta.  The keynote and APCaRI member speakers gave inspiring and informative talks.

We are especially appreciative of the participants representing patient advocacy groups, urologists, oncologists, funders, clinicians, trainees, and researchers who engaged in lively and productive conversation!

This year APCaRI also celebrated the many years of service from outgoing APCaRI Co-chairs Drs John Lewis and Eric Hyndman and welcomed incoming Co-chairs, Drs Adam Kinnaird, and Steven Yip.

Thank you again to our sponsors Astellas, AstraZeneca, Bayer, Janssen, Merck, and Pfizer who made this symposium possible.

APCaRI looks forward to seeing all of you again soon!

 

- Perrin Beatty